newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

  • Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) will host a conference call & live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss Q2 2026 financial results & provide a corporate update.
  • The call can be accessed via domestic telephone at 1-800-225-9448 or international at 1-203-518-9708 using conference ID VERRICA, with participants advised to dial in 10 minutes early.
  • A live audio webcast is available on www.verrica.com, with a replay archived for 90 days post-event.
  • Verrica's product YCANTH® (VP-102) is the sole FDA-approved healthcare professional-administered treatment for molluscum contagiosum in patients aged two years & older.
  • YCANTH® (VP-102) is also in development for common warts, identified as a major unmet need in medical dermatology.
  • Verrica holds a worldwide license agreement with Lytix Biopharma AS to develop & commercialize VP-315 (ruxotemitide) for non-melanoma skin cancers, including basal cell & squamous cell carcinoma.